Lilly reports full Q4 2024 financial results and provides 2025 guidance
Published on February 10, 2025
Eli Lilly and Company has recently released its financial results for the fourth quarter of 2024 along with its guidance for the year 2025. The pharmaceutical giant reported strong growth in its revenue, exceeding expectations and showcasing its ability to adapt and succeed in the face of challenges. Despite a slight decline in weight loss diabetes drug sales, Eli Lilly managed to beat earnings estimates, reflecting the company's diverse product portfolio and commitment to innovation. Looking ahead, the company provided an optimistic outlook for 2025, projecting further growth and advancements in its pipeline of therapies. With a solid performance and promising future prospects, it could be worth considering the opinion of professionals at Stocks Prognosis for an expert forecast on the movement of Eli Lilly's stock.
Investor opinions & comments
To leave a comment, you need to Login or Register.
TraderTobias
February 13, 2025 at 12:16
Eli Lilly's continued advancements in therapies and research give me hope for the future of healthcare
MarketMason
February 13, 2025 at 12:14
Eli Lilly's commitment to innovation and diverse product portfolio give me confidence in their long-term growth
CalebBishop
February 13, 2025 at 12:10
The strong performance of Eli Lilly's stock reflects the company's resilience and strategic approach
MoneyMartha
February 13, 2025 at 04:16
It's impressive to see Eli Lilly's revenue growth exceeding expectations. They must be doing something right
TylerGonzalez
February 13, 2025 at 03:39
I have high hopes for Eli Lilly's future. They have proven their ability to adapt and excel in a challenging market
MoneyMandy
February 12, 2025 at 23:23
I trust the professionals at Stocks Prognosis to provide an expert forecast on the movement of Eli Lilly's stock
SavingsSandy
February 12, 2025 at 07:06
Eli Lilly's solid Q4 results and positive outlook for 2025 demonstrate their ability to navigate challenges in the pharmaceutical industry
JeremiahSnyder
February 12, 2025 at 05:47
I have confidence in Eli Lilly's leadership to continue driving growth and success in the coming years
SadieColeman
February 12, 2025 at 05:09
I'm eager to hear more about Eli Lilly's pipeline of therapies and advancements in the coming year
CharlesGrant
February 12, 2025 at 00:12
Great news! I'm excited to see Eli Lilly's strong growth and optimistic outlook for 2025
CashKendra
February 11, 2025 at 17:25
Eli Lilly's financial results and guidance show that they are on the right track for future success
JosephMorris
February 11, 2025 at 14:15
The positive financial results and optimistic outlook make me believe that Eli Lilly's stock could be a smart investment
JessicaMoore
February 11, 2025 at 12:31
I'm not sure if Eli Lilly can sustain this level of growth. The decline in weight loss diabetes drug sales is concerning
MoneyMartha
February 10, 2025 at 19:08
I'm not convinced that Eli Lilly's diverse product portfolio can make up for the decline in one of their major sales categories
SavingsSam
February 10, 2025 at 17:07
I'm skeptical about Eli Lilly's guidance for 2025. It's hard to predict the future of the pharmaceutical industry
NicholasEdwards
February 10, 2025 at 12:54
I'm optimistic about Eli Lilly's future prospects. Their ability to adapt and succeed sets them apart from other pharmaceutical companies
GrowthGreg
February 10, 2025 at 12:42
Eli Lilly's strong growth in revenue highlights their ability to meet the demands of the market and drive success
StockSteve
February 10, 2025 at 08:38
Eli Lilly's ability to beat earnings estimates shows their strength as a company and their commitment to innovation
PennyParker
February 10, 2025 at 07:04
I'm looking forward to seeing the advancements and breakthroughs that Eli Lilly will bring in 2025